Are you still recruiting for “hypertension”… or for the full cardiometabolic reality your protocol actually requires?
Hypertension used to be treated (and recruited) as a single-variable disease: elevated blood pressure.
That model no longer reflects clinical reality.
Today’s hypertension patient is increasingly part of a broader cardiometabolic profile: obesity, insulin resistance, type 2 diabetes, and cardiovascular risk factors are deeply interconnected. Emerging research continues to show that therapies targeting weight and metabolic pathways (including GLP-1–based treatments) also drive meaningful reductions in blood pressure.
For sponsors, this changes more than treatment strategy. It changes recruitment strategy.
Because the patient you need is no longer “someone with high blood pressure.”
It’s someone with the right combination of conditions, history, and treatment status.
At the top of the funnel, hypertension still looks like a high-volume opportunity.
And it is.
In a recent hypertension Market Feasibility Test by Antidote powered by 83bar, 215 people completed a screener in just 2 days, with 96.7% confirming they had high blood pressure and 67.3% reporting systolic readings ≥140 mmHg.
The audience is there and easy to reach.
But this is where many trials break down.
Because once eligibility layers are applied (medication requirements, comorbidities, prior treatment history), the funnel tightens fast. What looks like scale at the top becomes friction at the site level.
That is why hypertension recruitment is no longer a volume problem.
It is a qualification and progression problem.
As protocols evolve, so does eligibility complexity.
Patients may need:
This is not theoretical because it shows up operationally.
In a global hypertension clinical program focused on renal denervation, 165,000 patients were pre-screened, 55,000 were screened, but only 15,000 were referred to sites—despite strong initial reach.
Cardiometabolic recruitment introduces layered filtering. Without early qualification, those filters shift downstream (into sites) where they become screen failures, coordinator burden, and timeline risk.
If hypertension is now a cardiometabolic condition, recruitment must evolve to match it.
That means:
When done correctly, this changes outcomes.
In the same hypertension program, structured pre-screening and patient engagement supported >90% of study procedures (randomizations), demonstrating that better qualification upstream leads to stronger progression downstream.
Hypertension trials have not become harder because patients are harder to find.
They have become harder because the definition of the “right patient” has changed.
The question is no longer: Can you reach people with high blood pressure?
It is: Can you identify and move forward the right cardiometabolic patient before your sites absorb the cost?